Ultrasound Contrast-Enhanced Accurate Diagnosis of Preoperative Staging of Bladder Cancer
Launched by SUN YAT-SEN MEMORIAL HOSPITAL OF SUN YAT-SEN UNIVERSITY · Jan 10, 2025
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new method for accurately diagnosing the stage of bladder cancer before surgery using a special ultrasound technique called contrast-enhanced ultrasound (CEUS). The goal is to improve the way doctors assess how advanced the cancer is, which is important for making treatment decisions. Preliminary results have shown that this method is quite effective, with high accuracy in identifying the cancer stage. The study will also explore combining CEUS with MRI (another imaging technique) to further enhance diagnostic precision.
To participate in this trial, individuals must be at least 18 years old and have a confirmed diagnosis of primary bladder cancer. It's important that they have not received any prior treatments like surgery or chemotherapy before the ultrasound procedure. Participants can expect to undergo the ultrasound examination and, if they qualify, contribute to developing a better diagnostic system for bladder cancer. This research aims to provide clearer information for doctors and improve care for patients facing bladder cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • (a) eligible patients should be 18-year-old or older;
- • (b) patients should have a histologically or cytologically confirmed diagnosis of primary bladder cancer;
- • (c) patients should not have had any surgery, chemotherapy, immunotherapy, or any therapy before CEUS diagnosis.
- Exclusion Criteria:
- • (a) participants with confirmed to have no carcinoma of the bladder;
- • (b) participants with previous pelvic surgery, who had undergone therapy, any bladder surgery, or had received chemotherapy, radiotherapy or immunotherapy;
- • (c) participants diagnosed with tumor recurrence or metastasis; (d) participants who were allergic to ultrasound contrast agents or could not tolerate CEUS examination, for instance, with recent myocardial infarction, angina pectoris, cardiac insufficiency, severe cardiac arrhythmia, a right/left cardiac shunt, severe pulmonary hypertension, uncontrolled systemic hypertension, acute respiratory distress syndrome, or chronic obstructive pulmonary disease.
About Sun Yat Sen Memorial Hospital Of Sun Yat Sen University
Sun Yat-sen Memorial Hospital of Sun Yat-sen University is a leading academic medical institution located in Guangzhou, China, renowned for its commitment to advancing healthcare through innovative clinical research and patient-centered care. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields, including oncology, cardiology, and infectious diseases, to conduct rigorous studies aimed at improving treatment outcomes and enhancing patient welfare. With a focus on collaboration and scientific excellence, the hospital is dedicated to translating research findings into practical applications that benefit both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Trial Officials
Luo, Prof.
Study Director
Department of Ultrasound in Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported